MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2

touchMDT for touchONCOLOGY   Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.   The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Pathologist – Prof. Albrecht Stenzinger University of Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs outside of the UK  only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/